- Earlier this year, Viking Therapeutics began a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist being tested as a potential obesity treatment in adults with excess weight.
- This first-in-human study expands Viking’s obesity pipeline beyond its GLP‑1/GIP program, highlighting a multi-mechanism approach that could broaden its future treatment profile if development progresses successfully.
- We’ll now examine how adding VK3019 as an early-stage obesity candidate could influence Viking Therapeutics’ broader investment narrative and risk profile.
The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation
Advertisement
Viking Therapeutics Investment Narrative Recap
To own Viking Therapeutics today, you need to believe its obesity franchise, led by VK2735, can eventually turn large R&D losses into meaningful revenue despite intense competition and zero current sales. The launch of VK3019 broadens the story beyond a single mechanism, but this Phase 1 trial does not change the near term focus on VANQUISH Phase 3 readouts as the key catalyst or the company’s heavy cash burn as the main risk
The VK3019 first in human trial fits beside Viking’s existing programs, but the most relevant recent update is the progress around VK2735, including VANQUISH-2 enrollment and oral Phase 3 planning. Those late stage obesity programs, supported by ECO data showing double digit <a href="https://healthylife7.com/public-perceptions-around-weight-loss-drugs-in-the-uk-revealed/" title="Public Perceptions Around Weight Loss Drugs in the UK Revealed”>weight loss with oral VK2735, remain central to whether current valuation, recent share price strength and optimistic analyst targets can be justified over time
Yet while VK3019 adds a new angle, investors should also be aware of the risk that continued high R&D spending without near term revenue could
Read the full narrative on Viking Therapeutics (it’s free!)
Viking Therapeutics’ narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires an earnings increase of about $372.5 million from -$359.6 million today
Uncover how Viking Therapeutics’ forecasts yield a $92.72 fair value, a 132% upside to its current price
Exploring Other Perspectives
Compared with consensus, the most optimistic analysts were modeling about US$497.5 million of revenue and US$62.2 million of earnings by 2029, so VK3019’s launch may either reinforce that bullish view or prompt you to reconsider how concentrated those expectations still are in VK2735’s success
Explore 12 other fair value estimates on Viking Therapeutics – why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts
- A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
- Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Viking Therapeutics’ overall financial health at a glance.
Ready For A Different Approach?
Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
- Find 44 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 52 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:VKTX
Viking Therapeutics
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders
See The Free Research Report
Flawless balance sheet with very low risk
See The Free Research Report
Market Insights
Q-Day: The risk the market forgot to repriceRichard Bowman
Finding dividends that actually lastMitchell Lawler
Watt’s left in the overcrowded power trade?Richard Bowman
Advertisement
Weekly Picks
LO
Lou_Baseneseon Giftify·3 months ago
Giftify ($GIFT): A Small-Cap Incentives Platform with More ScaleThan Its Valuation Suggests
Fair Value:US$2.561.6% undervalued
46followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
HA
HarishPKon lululemon athletica·30 days ago
Quantifying the Transition: Why Lululemon’s Moat Remains Intact
Fair Value:US$161.829.8% undervalued
21followersusers have followed this narrative
·2commentsusers have commented on this narrative
·9likesusers have liked this narrative
TR
tripledubon Alphabet·about 1 month ago
Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late
Fair Value:US$23057.4% overvalued
50followersusers have followed this narrative
·1commentusers have commented on this narrative
·13likesusers have liked this narrative
JO
John_Ericon Veeva Systems·6 days ago
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Fair Value:US$32041.2% undervalued
29followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
RecentlyUpdated Narratives
RI
richard_53rymon Nintendo·about 1 hour ago
Nintendo facing the Ram shortage situation
Fair Value:JPÂ¥8k11.0% undervalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
RO
RockeTelleron Rio Silver·about 4 hours ago
Rare Pure High Grade Silver with 35% Insider (Near Producer)
Fair Value:CA$2298.8% undervalued
14followersusers have followed this narrative
·5commentsusers have commented on this narrative
·0likesusers have liked this narrative
RO
RockeTelleron Ares Strategic Mining·about 8 hours ago
Ares Strategic Mining: $250M Pentagon Contract vs C$76M Market Cap
Fair Value:CA$0.9371.0% undervalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·21 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75030.7% undervalued
85followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·17 days ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5456.3% undervalued
61followersusers have followed this narrative
·3commentsusers have commented on this narrative
·10likesusers have liked this narrative
HA
HarishPKon Adobe·28 days ago
Adobe: A Probabilistic Case for Undervaluation
Fair Value:US$319.9630.9% undervalued
64followersusers have followed this narrative
·9commentsusers have commented on this narrative
·19likesusers have liked this narrative
